Exploratory, Pilot Study: Treatments accessed by caregivers of children with Down Syndrome - An internet survey
MetadataShow full item record
This item's downloads: 1 (view details)
Neil, NIcole, Fiani, Theresa, Mannion, Arlene, & Lynch, Meagan. (2018). Exploratory, Pilot Study: Treatments accessed by caregivers of children with Down Syndrome - An internet survey. Journal on Developmental Disabilities, 23(2) :37-49.
Down syndrome is associated with a range of developmental strengths and challenges. The treatment use of individuals with Down syndrome along with associated factors have not yet been determined. In a pilot study to address this issue, we elected to conduct an online survey rather than a classical representative population survey to generate relevant information quickly. An online survey was completed by 162 primary caregivers of children and youth with Down syndrome. Caregivers reported the types of treatments children were currently receiving and had received in the past, along with the overall satisfaction with treatments. Associations with other child variables (e.g., age, gender, and race) and family characteristics were also examined. Findings indicate that children were currently receiving a mean of 6.1 (SD = 3.5) different types of therapy treatments; the most common treatments was speech language therapy currently received by 73%. Only 2.4% of children were currently receiving applied behaviour analytic treatment, an empirically supported therapy. Caregivers reported using a number of treatments without empirical support including facilitated communication, holding therapy, and auditory/sensory integration. Caregivers tended to agree that each treatment was efficacious and contributed to their child s growth. Treatments that were associated with strong agreement included medication (69.8%), care from family and friends (62.8%), assistive technology (58.3%), and floortime (55.6%). Future research should focus on understanding the process of treatment selection by caregivers of children with Down syndrome and develop accessible guidelines on empirically supported therapies.
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.
The following license files are associated with this item: